Market Cap 1.30B
Revenue (ttm) 0.00
Net Income (ttm) -47.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,113,200
Avg Vol 2,326,162
Day's Range N/A - N/A
Shares Out 121.78M
Stochastic %K 67%
Beta 0.74
Analysts Strong Sell
Price Target $20.36

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 304 2499
Address:
195 Church Street, 16th Floor, New Haven, United States
Bfunk17
Bfunk17 Oct. 24 at 8:20 PM
$TRVI Institutional Ownership ticked up to 103.4% on Fintel. It is very interesting how they keep accumulating here at these levels. Love it.
0 · Reply
KINGKASHH
KINGKASHH Oct. 24 at 11:12 AM
$TRVI when the whole market dipped, this did not.
0 · Reply
ZR92x
ZR92x Oct. 23 at 8:23 PM
$TRVI Top 3 buyout candidates (in no particular order) - 1) Boehringer Ingelheim 2) Merck 3) Insmed
1 · Reply
Soheil444
Soheil444 Oct. 21 at 7:45 PM
$TRVI you’re a beast! too bad for ppl who dont know about this treasure
2 · Reply
Soheil444
Soheil444 Oct. 16 at 2:00 PM
$TRVI beautiful
0 · Reply
Bfunk17
Bfunk17 Oct. 15 at 9:09 PM
$TRVI Stay solid my friends. Buyout is coming for us. Everything is coming together here. Be patient. GL to you.
2 · Reply
abcdzepeda
abcdzepeda Oct. 15 at 7:11 PM
$TRVI 11.00 by EOD?
0 · Reply
ZR92x
ZR92x Oct. 15 at 1:42 PM
$TRVI News imminent?
0 · Reply
JFDI
JFDI Oct. 15 at 1:23 PM
$TRVI @Doozio yo long this thing? mjthwaites on X all over it.
2 · Reply
abcdzepeda
abcdzepeda Oct. 14 at 5:04 PM
$TRVI We running! 
0 · Reply
Latest News on TRVI
Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 29, 2025, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences


Trevi Therapeutics to Participate in Upcoming June Conferences

May 29, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences


Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 11, 2025, 4:16 AM EDT - 5 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript


Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 6:47 PM EDT - 7 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript


Bfunk17
Bfunk17 Oct. 24 at 8:20 PM
$TRVI Institutional Ownership ticked up to 103.4% on Fintel. It is very interesting how they keep accumulating here at these levels. Love it.
0 · Reply
KINGKASHH
KINGKASHH Oct. 24 at 11:12 AM
$TRVI when the whole market dipped, this did not.
0 · Reply
ZR92x
ZR92x Oct. 23 at 8:23 PM
$TRVI Top 3 buyout candidates (in no particular order) - 1) Boehringer Ingelheim 2) Merck 3) Insmed
1 · Reply
Soheil444
Soheil444 Oct. 21 at 7:45 PM
$TRVI you’re a beast! too bad for ppl who dont know about this treasure
2 · Reply
Soheil444
Soheil444 Oct. 16 at 2:00 PM
$TRVI beautiful
0 · Reply
Bfunk17
Bfunk17 Oct. 15 at 9:09 PM
$TRVI Stay solid my friends. Buyout is coming for us. Everything is coming together here. Be patient. GL to you.
2 · Reply
abcdzepeda
abcdzepeda Oct. 15 at 7:11 PM
$TRVI 11.00 by EOD?
0 · Reply
ZR92x
ZR92x Oct. 15 at 1:42 PM
$TRVI News imminent?
0 · Reply
JFDI
JFDI Oct. 15 at 1:23 PM
$TRVI @Doozio yo long this thing? mjthwaites on X all over it.
2 · Reply
abcdzepeda
abcdzepeda Oct. 14 at 5:04 PM
$TRVI We running! 
0 · Reply
lob11
lob11 Oct. 14 at 4:51 PM
$TRVI Finally broke 10. Need some follow thru
0 · Reply
ZR92x
ZR92x Oct. 14 at 3:41 PM
$TRVI Someone just dropped $5 million today buying 500,000 shares at $10 just a bit ago. Nice price action today. Also....I did some analysis on the unusual call options activity back in August for the September 19th expiry. Remember the 15,000 call options open interest in Trevi call options last month? Well.. that same day in late August when someone was going ham on Trevi options buying the 15,000 September 19th $7 call options, there was also unusual call options buying activity for Protagonist Therapeutics for the same September 19th dated expiry. Just last Friday, Johnson and Johnson just announced they are in talks to to buyout Protagonist Therapeutics (PTGX). Coincidence? Maybe, but we shall see...
2 · Reply
Bfunk17
Bfunk17 Oct. 13 at 9:45 PM
$TRVI Following up on ZR92x's excellent DD: How Boehringer Ingelheim is buttressing its US business | Fierce Pharma https://share.google/Amkx5S6jqgTMJfwEv Interview audio is available in middle of the page. Boehringer US head said a few very intriguing things: -They love launching new drugs -They want to be #1 in IPF as ZR92x pointed out -They prefer to buy preclinical entities, not FDA approved or late-stage molecules/drugs Everything they said fits Trevi as a potential BO target.
0 · Reply
ZR92x
ZR92x Oct. 13 at 1:39 PM
$TRVI Executive with Boehringer Ingelheim just did an interview with Fierce Pharma and said Boehringer wants to become an industry leader in the IPF space with Ofev and their just newly approved IPF drug. They just canceled their chronic cough drug in Phase 2 because the results were bad after they did a futility analysis at 4 weeks in. They need to acquire Trevi to get into chronic cough or else they wont be the leaders with a best in class IPF portfolio
1 · Reply
Bfunk17
Bfunk17 Oct. 11 at 2:06 PM
$TRVI Trevi Therapeutics Completes Key Phase 1 Drug Interaction Study - TipRanks.com https://share.google/U9Jjm8wb6avCUMi7F
2 · Reply
jlcrane
jlcrane Oct. 10 at 7:50 PM
$TRVI Let's close above the IPO price, finally.
1 · Reply
abcdzepeda
abcdzepeda Oct. 9 at 12:32 AM
$TRVI TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, to be held from October 19 to 22 in Chicago, Illinois.
0 · Reply
Bfunk17
Bfunk17 Oct. 7 at 2:44 PM
$TRVI Non-IPF ILD protocol meeting results with FDA due any day. Additionally, trial design talks with FDA for P3 IPF. Both of these PRs should be incoming over the next 2 months and set up Trevi for its future. Of course, landing the non-IPF design with the FDA would be tremendous. Haduvio would be lined up for 3 indications if this comes through.
0 · Reply
Bfunk17
Bfunk17 Oct. 5 at 12:31 PM
$TRVI Updated this morning. Continued powerful accumulation and Tute ownership here.
1 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 7:48 PM
$TRVI: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $3 Exp on 01/21/2028 with Premium of $180K and showing NEUTRAL Sentiment
1 · Reply
Bfunk17
Bfunk17 Oct. 3 at 2:42 PM
$TRVI Solid movement upward as expected. Looking good overall.
2 · Reply
Bfunk17
Bfunk17 Oct. 1 at 12:41 AM
$TRVI Really nice build occurring here. The 1-year is powerful combined with whispers of an incoming BO. Time will tell...but this company's science is incredibly impressive. 🤝
0 · Reply